Literature DB >> 26968978

Exogenous hydrogen sulphide ameliorates diabetic cardiomyopathy in rats by reversing disordered calcium-handling system in sarcoplasmic reticulum.

Yu-Si Cheng1, De-Zai Dai2, Yin Dai2, Dong-Dong Zhu1, Bi-Cheng Liu1.   

Abstract

OBJECTIVES: Hydrogen sulphide (H2 S) has been found to be involved in cardiovascular diseases, but the exact mechanism has not been clarified. The purpose of this study was to investigate whether sodium hydrogen sulphide (NaHS), the donor of H2 S, can improve diabetic cardiomyopathy by reversing disordered calcium-handling system in sarcoplasmic reticulum (SR).
METHODS: Sprague Dawley rats were injected with streptozotocin (STZ, 60 mg/kg, i.p.) to build diabetic model. Treatment groups included: aminoguanidine group (AG, 100 mg/kg, p.o.) and NaHS group (5 mg/kg per day, s.c.). KEY
FINDINGS: Cardiac dysfunction and myocardial hypertrophy were found in diabetic model (DM) group, along with increased ROS levels and upregulated mRNA and protein expressions of NADPH p22(phox) , endothelin A receptor (ETA ) and protein kinase Cε (PKCε). Expressions of calcium-handling proteins in SR including FK506-binding proteins (FKBP12.6), sarcoplasmic reticulum Ca(2+) ATPase (SERCA2a) and calsequestrin 2 (CASQ2) were downregulated in DM group, accompanied by elevated concentration of diastolic free calcium in high glucose-incubated cardiomyocytes, indicating of calcium leak. After treated by NaHS, these abnormalities were attenuated significantly.
CONCLUSIONS: Exogenous H2 S played a protective role in diabetic cardiomyopathy by inhibiting abnormal calcium-handling system in SR and ET-NADPH oxidase-PKCε pathway.
© 2016 Royal Pharmaceutical Society.

Entities:  

Keywords:  CASQ2; FKBP12.6; NADPH p22phox; SERCA2a; diabetic cardiomyopathy

Mesh:

Substances:

Year:  2016        PMID: 26968978     DOI: 10.1111/jphp.12517

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Protein S-sulfhydration by hydrogen sulfide in cardiovascular system.

Authors:  Guoliang Meng; Shuang Zhao; Liping Xie; Yi Han; Yong Ji
Journal:  Br J Pharmacol       Date:  2017-05-24       Impact factor: 8.739

2.  Hydrogen Sulfide Ameliorates Lipopolysaccharide-Induced Memory Impairment in Mice by Reducing Apoptosis, Oxidative, and Inflammatory Effects.

Authors:  Viplav Kshirsagar; Chetan Thingore; Malvika Gursahani; Nitin Gawali; Archana Juvekar
Journal:  Neurotox Res       Date:  2021-05-22       Impact factor: 3.911

3.  Myricitrin Alleviates Oxidative Stress-induced Inflammation and Apoptosis and Protects Mice against Diabetic Cardiomyopathy.

Authors:  Bin Zhang; Qiang Shen; Yaping Chen; Ruile Pan; Shihuan Kuang; Guiyan Liu; Guibo Sun; Xiaobo Sun
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

4.  Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2.

Authors:  Amir Hossein Heydari; Mojtaba Fathi; Sophia Heydari; Mohammad Esmaeil Heidari
Journal:  Cardiovasc Ther       Date:  2022-03-27       Impact factor: 3.023

5.  Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus.

Authors:  R Gimenes; C Gimenes; C M Rosa; N P Xavier; D H S Campos; A A H Fernandes; M D M Cezar; G N Guirado; L U Pagan; I D Chaer; D C Fernandes; F R Laurindo; A C Cicogna; M P Okoshi; K Okoshi
Journal:  Cardiovasc Diabetol       Date:  2018-01-17       Impact factor: 9.951

6.  Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.

Authors:  Bin Zhang; Jingyi Zhang; Chenyang Zhang; Xuelian Zhang; Jingxue Ye; Shihuan Kuang; Guibo Sun; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

7.  Protective Effects of Allicin on Acute Myocardial Infarction in Rats via Hydrogen Sulfide-mediated Regulation of Coronary Arterial Vasomotor Function and Myocardial Calcium Transport.

Authors:  Tianwei Cui; Weiyu Liu; Chenghao Yu; Jianxun Ren; Yikui Li; Xiaolu Shi; Qiuyan Li; Jinyan Zhang
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.